Drug Trial Radar · NCT06828887
Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Apr 3, 2025
Primary completion
Sep 1, 2027
Study completion Dec 20, 2027
Sponsor
- Lead sponsor
- Vigonvita Life SciencesIndustry
- Sponsor type
- Industry
- First posted
- Feb 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding Phase II clinical trial aimed to determine the optimal dose of LV232 capsules for treating MDD, evaluate preliminary efficacy and safety, and provide a basis for Phase III trial design and dosing regimen determination.
Conditions
- MDD
Interventions
LV232 40mgDrug
LV232 capsules 2 capsules (20 mg/capsule) + LV232 capsule placebo 1 capsule + escitalopram oxalate tablet placebo 1 tablet
LV232 60mgDrug
LV232 capsules 3 capsules (20 mg/capsule) + escitalopram oxalate tablet placebo 1 tablet
EscitalopramDrug
LV232 capsule placebo 3 capsule + escitalopram oxalate tablet 1 tablet
PlaceboDrug
LV232 capsule placebo 3 capsule + escitalopram oxalate tablet placebo 1 tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Montgomery Asperger Depression Scale (MADRS) score at the end of treatment (week 8)Time frame: Baseline and week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Mental Health Center Ethics Committee
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.